| Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with H. |
businesswire.com |
2025-05-13 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria's common stock on May 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted. |
businesswire.com |
2025-05-02 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria's common stock on April 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante. |
businesswire.com |
2025-04-02 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's common stock on March 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante. |
businesswire.com |
2025-03-04 18:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025. Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institut. |
businesswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics: A High-Conviction Bet On HAE |
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. |
seekingalpha.com |
2025-02-18 00:32:44 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria's common stock on February 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gra. |
businesswire.com |
2025-02-04 18:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii from Sunday, February 9 through Thursday, February 13, 2025. Dr. Marc A. R. |
businesswire.com |
2025-02-03 10:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other indications. The Phase 1a trial is inte. |
businesswire.com |
2025-01-23 10:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria's common stock on January 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran. |
businesswire.com |
2025-01-03 18:10:00 |
Czytaj oryginał (ang.) |
| Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? |
Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year. |
zacks.com |
2024-12-17 12:40:40 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's common stock on December 2, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gra. |
businesswire.com |
2024-12-03 18:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema |
Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. |
seekingalpha.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter of execution for both navenibart and STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We are excited about the opportunity for navenibar. |
businesswire.com |
2024-11-13 18:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 52,000 shares of Astria's common stock on October 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran. |
businesswire.com |
2024-10-02 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming Global Angioedema Forum |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024. Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospit. |
businesswire.com |
2024-09-27 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and. |
businesswire.com |
2024-09-19 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on September 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were g. |
businesswire.com |
2024-09-04 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New York. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic. |
businesswire.com |
2024-08-29 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria's common stock on June 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grant. |
businesswire.com |
2024-06-04 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6th at 10:00am ET in New York, NY. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288. |
businesswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming Eastern Allergy Conference |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024. Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, “Updated Results of a Ph. |
businesswire.com |
2024-05-24 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024. Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a l. |
businesswire.com |
2024-05-23 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We are thrilled with the ALPHA-STAR initial proof-of-concept results that we shared in March, and believe that STAR-0215 can be a life-changing therapy for people living with HAE,” said Jill C. Milne, Ph.D.,. |
businesswire.com |
2024-05-09 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024. Dr. Chunxia Lily Zhao, Director of Antibody Discovery at Astria Therapeutics, will present a poster titled, “Preclinical. |
businesswire.com |
2024-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of Astria's common stock on April 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grant. |
businesswire.com |
2024-04-03 20:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE |
BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate a favorable safety and tolerability profile, mean monthly atta. |
businesswire.com |
2024-03-25 09:30:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria's common stock on March 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran. |
businesswire.com |
2024-03-05 18:10:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update |
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “We have strong conviction in the potential for STAR-0215 to be the first-choice preventative therapy for HAE,” said Jill C. Milne, Chief Executive Officer at Astria Therapeutics. “Our final. |
businesswire.com |
2024-03-04 18:10:00 |
Czytaj oryginał (ang.) |